Silence Therapeutics said divesiran stabilized red blood cell levels in a Phase 2 PV trial, a result the company believes could position it against major upcoming options. In the 48-patient study, Silence reported that 88% of participants receiving divesiran at six- or 12-week dosing intervals achieved clinical response versus 19% on placebo. The trial’s readout arrives as the PV market eyes drugs from Takeda and Protagonist’s rusfertide, raising the competitive bar for any new entrant that seeks regulatory momentum. Silence’s data also strengthen the rationale for advancing toward later-stage testing where durable response and safety tolerability become the differentiators. For biotech decision-makers, the update clarifies how far divesiran has progressed in proving activity under randomized conditions, rather than relying solely on early biomarker or response indicators.